A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children

Sponsor
The University of Hong Kong (Other)
Overall Status
Unknown status
CT.gov ID
NCT02459509
Collaborator
(none)
140
1
2
11
12.7

Study Details

Study Description

Brief Summary

The purpose of the study is to determine if 4mcg/kg of intranasal dexmedetomidine is better than 2mcg/kg in successfully sedating a child prior to induction of anesthesia.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

Dexmedetomidine is a selective alpha-2 adrenoreceptor agonist that has sedative, anxiolytic and analgesic properties without causing respiratory depression. It has been administered safely and effectively via a number of routes including as an intravenous infusion, intramuscularly, intranasally, buccally and orally .

Yuen et al established that the median time of onset of sedation is 25-30 minutes, making it an ideal agent for preoperative sedation. The same group also studied doses of 1 mcg/kg and 2 mcg/kg as a sedative premedication and found that the success rates of appropriate sedation at induction in children aged 1 to 8 years were 53% and 66% respectively, with a dose related increase in successful sedation.

Much higher doses of dexmedetomidine have also been used safely. Administered intravenously, 3mcg/kg of dexmedetomidine has been shown to provide satisfactory sedation for paediatric MRI in 97% of cases, without adverse effects.

The investigators aim to show that high dose intranasal dexmedetomidine is a safe, effective and an easily administered sedative premedication.

The investigators hypothesise that 4mcg/kg compared to 2mcg/kg of intranasal dexmedetomidine will lead to at least a 20% increase in the proportion of satisfactorily sedated patients at the time of anaesthesia induction.

The primary outcome will be the proportion of children with satisfactory sedation at the time of anaesthesia induction.

Suitable patients will be identified from the theatre lists and consent will be sought from their legal guardians during preassessment clinic or during their anaesthetic preoperative assessment on the ward.

In a previous study, 66% of children aged 1-5 years were satisfactorily sedated at the time of induction with 2 mcg/kg of intranasal dexmedetomidine. In order to find a 20% difference with 4 mcg/kg of dexmedetomidine, the investigators' sample size needs to be 140 (70 in each group), for a power of 0.8 and a 5% false positive rate.

The demographic data will be analysed by t test and chi-square test. The proportions of satisfactory sedation will be analysed by chi-square test. The onset sedation time and duration of sedation will be analysed by survival analysis. The vital signs over times will be expressed by percentage changes from baseline and estimated by mean and standard errors. A p-value<0.05 will be considered statistically significant.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
140 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children - a Double- Blind Randomised Controlled Trial
Study Start Date :
Jun 1, 2015
Anticipated Primary Completion Date :
May 1, 2016
Anticipated Study Completion Date :
May 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Dexmedetomidine 2 mcg/kg

2 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction

Drug: Dexmedetomidine
Either 2mcg/kg or 4mcg/kg of intranasal dexmedetomidine will be given to assess efficacy of preoperative sedation
Other Names:
  • Precedex
  • Active Comparator: Dexmedetomidine 4 mcg/kg

    4 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction

    Drug: Dexmedetomidine
    Either 2mcg/kg or 4mcg/kg of intranasal dexmedetomidine will be given to assess efficacy of preoperative sedation
    Other Names:
  • Precedex
  • Outcome Measures

    Primary Outcome Measures

    1. Satisfactory sedation [From 30 minutes post drug administration to induction of anaesthesia (average 30 minutes)]

      The primary outcome will be the proportion of children with satisfactory sedation at the time of anaesthesic induction.

    Secondary Outcome Measures

    1. Time to satisfactory sedation [From time of drug administration to when Observer's Assessment of Alertness/ Sedation Score is 2 or less (from 0 minutes to 30 minutes)]

      Time taken from drug administration to when the child's sedation level is that of only responding after mild prodding or shaking

    2. Blood pressure [From drug administration to end of anaesthesia (on average 1 to 3 hours)]

      Blood pressure will be taken every 5 minutes

    3. Heart rate [From drug administration to end of anaesthesia (on average 1 to 3 hours)]

      Heart rate will be taken every 5 minutes

    4. Oxygen saturations [From drug administration to end of anaesthesia (on average 1 to 3 hours)]

      Oxygen saturations will be taken every 5 minutes

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    6 Months to 5 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • All children of American Society of Anesthesiologists (ASA) physical status classification I or II (healthy) between the ages of 6 months and 5 years undergoing surgery at Queen Mary Hospital
    Exclusion Criteria:
    • Any patient receiving other sedative premedication, allergy to dexmedetomidine, organ dysfunction, cardiac arrhythmia and congenital heart disease.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Queen Mary Hospital Hong Kong Hong Kong

    Sponsors and Collaborators

    • The University of Hong Kong

    Investigators

    • Principal Investigator: Sophie E Liu, MBBS, Hong Kong University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    The University of Hong Kong
    ClinicalTrials.gov Identifier:
    NCT02459509
    Other Study ID Numbers:
    • UW 15-105
    First Posted:
    Jun 2, 2015
    Last Update Posted:
    Apr 18, 2016
    Last Verified:
    Apr 1, 2016
    Keywords provided by The University of Hong Kong
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 18, 2016